...
首页> 外文期刊>Analytical and bioanalytical chemistry >Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology
【24h】

Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology

机译:高效液相色谱-荧光光谱法同时检测和定量犬血浆中帕瑞昔布和伐地昔布:一种新方法的开发和验证

获取原文
获取原文并翻译 | 示例
           

摘要

Parecoxib is the injectable prodrug of valdecoxib, a cicloxygenase-2 selective drug, currently used in human medicine. Recent studies have suggested both its excellent clinical effectiveness and wide safety profile. The aim of the present study was to develop and validate a new high-performance liquid chromatography (HPLC) with spectrofluorimetric detection method to quantify parecoxib and valdecoxib in canine plasma. Several parameters both in the extraction and the detection method were evaluated. The applicability of the method was determined by administering parecoxib to one dog: the protocol provided the expected pharmacokinetic results. The final mobile phase was acetonitrile: AcONH_4 (10 mM; pH 5.0) 55:45, v/v, with a flow rate of 0.4 mL min~(-1), and excitation and emission wavelengths of 265 and 375 nm, respectively. The analytical column was a reverse-phase C18 ODS2 3-μm particle size. Protein precipitation in acidic medium followed by two successive liquid-liquid steps was carried out. The best extraction solvent was cyclohexane:Et_2O (3:2, v/v) that gave recoveries ranging from 81.1% to 89.1% and from 94.8% to 103.6% for parecoxib and valdecoxib, respectively. The limits of quantification were 25 and 10 ng mL~(-1) for parecoxib and valdecoxib, respectively. The chromatographic runs were specific with no interfering peaks at the retention times of the analytes, as confirmed by HPLC-mass spectrometry experiments. The other validation parameters were in agreement with the European Medicines Evaluation Agency and International Conference on Harmonisation guidelines. In conclusion, this method (extraction, separation and applied techniques) is simple and effective. This is the first time that use of a HPLC with spectrofluorimetric detection technique to simultaneously detect parecoxib and valdecoxib in plasma has been reported. This technique may have applications for pharmacokinetic studies. [Figure not available: see fulltext.]
机译:Parecoxib是valdecoxib的可注射前药,valdecoxib是一种cicloxygenase-2选择性药物,目前用于人类医学。最近的研究表明其出色的临床疗效和广泛的安全性。本研究的目的是开发和验证一种新型的高效液相色谱(HPLC),采用荧光光谱检测方法对犬血浆中的帕瑞昔布和伐地昔布进行定量。评价了提取和检测方法中的几个参数。该方法的适用性是通过将parecoxib给予一只狗来确定的:该方案提供了预期的药代动力学结果。最终的流动相为乙腈:AcONH_4(10 mM; pH 5.0)55:45,v / v,流速为0.4 mL min〜(-1),激发和发射波长分别为265和375 nm。分析柱的粒径为3μm的反相C18 ODS2。在酸性介质中进行蛋白质沉淀,然后进行两个连续的液-液步骤。最好的萃取溶剂是环己烷:Et_2O(3:2,v / v),帕瑞昔布和伐地昔布的回收率分别为81.1%至89.1%和94.8%至103.6%。帕瑞昔布和伐地昔布的定量限分别为25和10 ng mL〜(-1)。色谱运行是特定的,在分析物的保留时间没有干扰峰,这已通过HPLC-质谱分析实验证实。其他验证参数与欧洲药品评估局和国际协调会议指南一致。总之,此方法(提取,分离和应用技术)简单有效。据报道,这是首次使用具有荧光荧光检测技术的HPLC同时检测血浆中的帕瑞昔布和伐地昔布。该技术可能在药代动力学研究中有应用。 [图不可用:请参见全文。]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号